JONG AN, DO

Injection, fosnetupitant 235 mg and palonosetron 0.25 mg

Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Administration of chemotherapy into vein, 1 hour or less

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Established patient office or other outpatient visit, 40-54 minutes

New patient office or other outpatient visit, 45-59 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Established patient office or other outpatient visit, 30-39 minutes

Administration of additional new drug or substance into vein using push technique

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Injection, fulvestrant, 25 mg

Flow cytometry technique for dna or cell analysis, first marker

Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Drawing of blood for a medical problem

Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month

Injection, zoledronic acid, 1 mg

Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Infusion into a vein for hydration, 31-60 minutes

Established patient office or other outpatient visit, 20-29 minutes

Injection, pembrolizumab, 1 mg

Administration of chemotherapy into vein, each additional hour

Injection, carboplatin, 50 mg

Application of on-body injector for under skin injection

Flow cytometry technique for dna or cell analysis, each additional marker

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Injection, lanreotide, 1 mg

Injection, cisplatin, powder or solution, 10 mg

Injection of drug or substance into vein

Injection, daratumumab, 10 mg and hyaluronidase-fihj

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg

Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Injection, nivolumab, 1 mg

Injection, palonosetron hcl, 25 mcg

Irrigation of implanted venous access drug delivery device

Carcinoembryonic antigen (cea) protein level

Psa (prostate specific antigen) measurement, total

Collection of blood sample from implanted device

Injection of additional new drug or substance into vein

Beta-2 microglobulin (protein) level

Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3

Cyanocobalamin (vitamin b-12) level

Infusion into a vein for hydration, each additional hour

Injection of drug or substance under skin or into muscle